Beyond Contract Manufacturing: How Manufacturing Relationships are now a Competitive Advantage

The rise of biologics has introduced manufacturing complexity that didn't exist a decade ago. Monoclonal antibodies, stem cell therapies, and mRNA platforms all demand specialist capability. This session explores how manufacturing is moving from a back-office function to a strategic differentiator.

• The biologics manufacturing challenge: what's required for mAbs, stem cells, and mRNA, and who can deliver it
• API sourcing and supply chain resilience: where ingredient-level decisions create downstream risk
• Manufacturing strategy for start-ups: why your CDMO relationship is a founding decision, not an operational one
• COGS and commercial viability: how unit economics at the manufacturing stage determine whether a product can reach market
• Manufacturing as a diligence factor: what acquirers and investors look for in your CMC package